Classic Hodgkin lymphoma

The abnormal B cells are surrounded by many noncancerous immune cells in the affected tissue. A lymph-node biopsy distinguishes classic Hodgkin lymphoma from other lymphomas, including nodular lymphocyte-predominant B-cell lymphoma.

It can affect adolescents and adults of many ages. Scans, symptoms, blood tests and other findings establish the stage and help plan treatment. Advanced-stage Hodgkin lymphoma can still be treated with curative intent.

Changes in a B cell allow it to survive and evade immune control. Epstein-Barr virus is associated with a proportion of cases, but it is not present in all classic Hodgkin lymphoma and most people with EBV never develop the disease.

Immune dysfunction and family history can affect risk. The exact cause in an individual is usually unclear. The lymphoma is not contagious and does not arise from something a person failed to do.

Painless enlarged lymph nodes are a common presentation. Fever, drenching night sweats, weight loss, itching or fatigue may occur, and a chest mass may cause cough or pressure symptoms.

The extent of lymphoma and response on interim or end-of-treatment imaging help guide care. Symptoms alone cannot distinguish lymphoma from infection or other causes of swollen nodes.

Initial treatment uses combination drug therapy, with radiotherapy in selected circumstances. The regimen may include chemotherapy, brentuximab vedotin or a PD-1 checkpoint inhibitor according to stage, age and clinical context. Response-adapted approaches try to control the lymphoma while limiting late effects.

For relapse or refractory disease, salvage treatment often aims to achieve a response followed by high-dose chemotherapy and autologous stem cell rescue. This is an established pathway for eligible patients and uses their own cells.

Allogeneic transplantation is considered for selected patients after failure of autologous treatment or other approaches. Checkpoint inhibitors and other medicines can produce substantial responses and affect transplant timing; prior immunotherapy also needs to be considered when planning a donor transplant.

Treatment can bring fatigue, nausea, infections and changes in daily routines. Fertility, heart and lung effects, second cancers and other late effects depend on the medicines and radiation exposure, so survivorship care is tailored to what a person received.

If transplant becomes part of care, recovery may include time near the center and support with meals, medicines and appointments. A good response on a scan is encouraging, but follow-up remains important and does not predict the same course for everyone.

Most people with classic Hodgkin lymphoma never need an unrelated stem cell donor. The more common transplant approach is autologous and uses the patient’s own collected cells.

When allogeneic transplantation is appropriate, a relative, unrelated registry volunteer or alternative graft can provide donated cells. Donor registration supports people who need that option; it does not replace standard first-line lymphoma treatment.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?